ORTEXORTEX News
Tracking ALAB? Get live short interest, options flow, and signals on ORTEX.Sign up free →
AL
Earnings PreviewALAB

ALAB Short Sellers Retreat Before Monday's Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 31 Oct 2026, 04:04

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Astera Labs enters its November 3 earnings report with short sellers pulling back sharply, even as the stock itself absorbed a punishing session on Friday.

Short interest has fallen to its lowest level in at least a year. Positions dropped 8.2% over the past week to 4.9% of free float, continuing a month-long retreat that has unwound roughly 14.6% of short exposure since late September. The borrow market reflects this: availability is extremely loose at 4,609%, meaning there are roughly 46 shares available to borrow for every one already lent out, well above the 52-week trough of 652%. Cost to borrow, at 0.53%, has crept up 42.9% over the past month but remains firmly low in absolute terms. Options positioning is close to neutral, with the put/call ratio at 0.92, barely above its 20-day average of 0.90 and only a third of a standard deviation from normal. The collective picture is one of shorts covering, not piling in, despite the stock falling 10.9% on Friday alone and losing 27.7% over the past month to close at $258.70.

The debate around Astera hinges on whether its AI connectivity franchise can sustain hypergrowth margins against a narrowing customer base. Bulls point to the most recent quarter's $308.4 million in revenue, up 93% year on year, alongside 76.4% gross margins, as evidence that the Aries, Taurus, and Scorpio product lines command genuine pricing power as hyperscalers accelerate PCIe Gen 6 deployments. The analyst consensus reflects that conviction: the mean price target stands at $382.68, roughly 48% above Friday's close, with most post-August target revisions skewed upward. Bears centre their case on customer concentration. The AWS warrant agreement makes the hyperscaler dependency explicit, and any softening in cloud capital expenditure would flow directly to Astera's top line. Gross margin pressure from product mix and an operating expense step-up already appeared in the last print, and competition from Broadcom, Marvell, and Credo in retimers and active electrical cables remains intense. TD Cowen, holding at Hold, cut its target from $375 to $300 in mid-October, a meaningful signal that patience on valuation is thinning even among neutral-rated analysts.

The stock's Friday drop was idiosyncratic relative to peers. LRCX, AMAT, and AMD each gained between 10.5% and 12.3% over the past week, while MRVL, the closest competitor in AI connectivity silicon, fell 13.2% on the day and shed 2.3% on the week. That ALAB underperformed its closest peers by roughly 10 percentage points on a weekly basis, even as short interest was unwinding, points to selling pressure rooted in fundamental reassessment rather than short-side momentum. Insider activity over the past 90 days reinforces some caution: the net position across all reported transactions runs to approximately $90 million in net sales, though the bulk of these were executed under pre-arranged 10b5-1 plans, which limits their read-across as discretionary signals.

Monday's print will test whether the revenue trajectory justifies a market capitalisation of $44.9 billion at a trailing price-to-earnings ratio of 48 times, and whether gross margins held or compressed further in the September quarter.

Stocks in this article

See the live data behind this article on ORTEX.

Open ALAB on ORTEX →

How this article was generated

Generated
31 Oct 2026, 04:35
Data as of
31 Oct 2026, 04:04
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.